ROBOSENSE
21.4.2021 20:02:15 CEST | Business Wire | Press release
RoboSense (https://www.robosense.ai/ ), the leading smart LiDAR sensor provider announced a strategic partnership with Banma Network Technology, an intelligent automobile operating system and solution provider that cooperated with Alibaba Group and SAIC Motor, and AutoX, China's most advanced self-driving AI platform, to build a high-level autonomous driving platform for intelligent vehicles through in-depth cooperation in the 3D LiDAR sensor, AI algorithm, and intelligent automobile operating system, and create an advanced smart cockpit based on human-machine co-driving.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005523/en/
The cooperation will promote the integration of smart cockpits with autonomous driving systems through the fusion of hardware, software, and AI capabilities. RoboSense will provide the robust LiDAR sensor solution that not only meets the need for high-level autonomous driving systems, but also for Banma's advanced intelligent cockpit systems. RoboSense LiDAR provides accurate environmental perception data for the AutoX autonomous driving system "AI driver", and empowers the safety of Banma's intelligent automobile operating system.
In January 2021, RoboSense and Banma jointly established the Intelligent Perception Innovation Center. Three months later, the two parties formed a mass-production-ready solution based on the intelligent automobile operating system and automotive-grade solid-state RS-LiDAR-M1, which meets the requirements of both autonomous passenger cars and the RoboTaxi.
The Executive President and Co-Founder of RoboSense, Mark Qiu said, " With three parties' efforts on the integration of intelligent cockpit system, perception system, and AI autonomous driving solution, we are able to provide a new generation of intelligent vehicle solutions with more potential values to OEMs and other customers."
The CIO of Banma, Qiang Xu said, " Intelligent interaction, intelligent service, and intelligent driving are the three basic aspects of smart driving cars. At present, smart cockpits and autonomous driving are gradually merging with each other. In terms of hardware, we provide RoboSense with system-level support to ensure its perception power is fully utilized. As for the algorithm, we provide AutoX with a rich toolchain, cloud and end service system to create a sustainable and efficient ecological collaboration system. "
The Founder and CEO of AutoX, Jianxiong Xiao said, "With the fully driverless RoboTaxi is becoming a reality in China, passengers will have more free time in the car. More intelligent services and interactions with the car are needed for a smart and enjoyable travel experience. A complete product ecosystem formed by three parties will create a safe and enjoyable autonomous driving solution. "
About RoboSense
RoboSense is the leading provider of Smart LiDAR Sensor Systems incorporating LiDAR sensors, AI algorithms and IC chipsets, that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. The company's mission is to possess outstanding hardware and artificial intelligence capabilities to provide smart solutions that enable robots (including vehicles) to have perception capability more superior to humans. https://www.robosense.ai/
About Banma
Banma provides an intelligent automobile operating system, intelligent automobile solutions as well as digital transportation solutions for both automotive and transportation industries. Powered by self-developed AliOS, Banma Automobile Solutions currently have collaborated with more than 1 million vehicles. In the future, Banma will promote transportation digitalization by providing man-machine co-driving and vehicle-road collaboration. https://www.ebanma.com
About AutoX
AutoX is the market leader for RoboTaxi in China. AutoX is the only company operating fully driverless RoboTaxi fleet on public roads in China without safety drivers. The company’s self-driving platform is capable of handling the densest and most dynamic traffic conditions in urban cities around the world. AutoX is the world's second permit holder for California DMV’s completely driverless RoboTaxi permit. https://www.autox.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005523/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom